...Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary...
...the time to run/walk 10 meters and the six-minute walk test vs. the lowest dose. ReveraGen BioPharma Inc....
...making Idorsia Ltd. (SIX:IDIA) its majority shareholder. Idorsia inherited the option to license vamorolone from ReveraGen...

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...

...company's investment in the pivotal Phase IIb VISION-DMD (VBP15-004) trial being conducted by DMD company ReveraGen BioPharma Inc....
...the latter's acquisition by Johnson & Johnson (NYSE:JNJ), inheriting Actelion's option to license vamorolone from ReveraGen...
...opt in for exclusive worldwide rights in exchange for a $20 million payment to ReveraGen. ReveraGen...

...an option to obtain exclusive, worldwide rights to vamorolone from ReveraGen BioPharma Inc. under a November deal. ReveraGen...
...year. (A) J&J has an option to ACT-132577; details are not disclosed; (B) In-licensed from ReveraGen BioPharma Inc....
...Switzerland AstraZeneca plc (LSE:AZN; NYSE: AZN), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. ReveraGen BioPharma Inc....

...Actelion and ReveraGen partnered to develop and commercialize vamorolone to treat Duchenne muscular dystrophy (DMD). Actelion...
...than prior to data from a planned Phase IIb trial. If Actelion exercises the option, ReveraGen...
...testing for DMD. ReveraGen BioPharma Inc. , Rockville, Md. Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Business: Musculoskeletal Nora Weintraub Actelion Ltd. ReveraGen BioPharma Inc. Nuclear...

...leucocytes to levels resembling that of wild-type mice. Data were published in EMBO Molecular Medicine. ReveraGen...
...reached for next steps for the dissociative glucocorticoid and inhibitor of NF-kappa B (NF-kB) . ReveraGen BioPharma Inc....

...projects Afraxis Inc. Not applicable p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitor Fragile X syndrome ReveraGen Biopharma Inc....

...to be an encumbrance to companies." The third and fourth partnerships include a project from ReveraGen BioPharma Inc....
...of a subgroup of patients with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). ReveraGen...
...Human Genome Research Institute , Bethesda, Md. NIH Center for Translational Therapeutics , Bethesda, Md. ReveraGen BioPharma Inc....

...and expects to open a third round this fall. Afraxis Inc. , La Jolla, Calif. ReveraGen Biopharma Inc....
...and laboratory resources, including funding. Business: Pharmaceuticals The projects are: VBP15, a dissociative glucocorticoid from ReveraGen...

...projects with R&D staff and laboratory resources, including funding. The projects are: a compound from ReveraGen Biopharma Inc....